Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
Innate Pharma is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases. These novel drugs consist of monoclonal antibodies that can activate the innate immune system.
Backed by Gilde as an investor, Innate Pharma has advanced its product pipeline to the clinical development stage and built strong commercial partnerships with Novo Nordisk and Bristol-Myers Squibb.
Innate Pharma operates from Marseille, France, and was successfully listed at Euronext Paris (IPH) after its IPO in 2006.
More Innate Pharma news
INNATE PHARMA initiates collaboration with Celgene
Innate Pharma reports positive phase IIa in type C viral hepatitis
INNATE PHARMA Swaps Products with NOVO NORDISK A/S to Obtain full Commercial Rights
Venture&Growth
Purespring Therapeutics
Founded in 2020, Purespring is a pioneering London (UK)-based gene therapy company focused on transforming treatments for patients suffering from chronic kidney diseases. It is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell
Venture&Growth
AM-Pharma
AM-Pharma is a Dutch biopharmaceutical company developing a biotherapeutic for the treatment of Sepsis Associated Acute Kidney Injury (SA-AKI).
Venture&Growth
Amphista Therapeutics
Amphista Therapeutics is a UK-based company creating first-class therapeutics to selectively degrade and remove disease-causing proteins by harnessing the body’s natural processes. It’s next generation targeted protein degradation TPD-based medicines leverage novel mechanisms that make use of a wider range
